(IN BRIEF) A collaborative study led by Bayer and Hurdle, in partnership with top academic institutions including the University of Birmingham and the University of Edinburgh, has introduced and validated InflammAge—a novel, non-invasive saliva-based biomarker that quantifies systemic chronic inflammation, … Read the full press release
Posted in Business, Education, European Union, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology, United Kingdom
Tagged aging, Bayer, Cancer, cardiovascular disease, chronic inflammation, CRP, Dr. Daniel Martin-Herranz, Generation Scotland, Hurdle, InflammAge, lifestyle factors, neurodegenerative disorders, non-invasive testing, partnership, precision medicine, Professor Janet M Lord, Professor Riccardo E. Marioni, remote health monitoring, saliva-based DNA methylation biomarker, University of Birmingham, University of Edinburgh, Veronika Óvári
(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adjuvant, AstraZeneca, clinical trial, Cristian Massacesi, durvalumab, early-stage, EFS, event-free survival, FLOT chemotherapy, gastric cancer, gastroesophageal junction, GEJ cancers, global, Imfinzi, immunotherapy, locally advanced, MATTERHORN, Memorial Sloan Kettering, neoadjuvant, OS, overall survival, pathologic complete response, PCR, Phase III Trial, randomized, resectable, safety profile, tumor regression, Yelena Y. Janjigian
(IN BRIEF) Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a hub that will drive breakthroughs in Cardiovascular, Renal, and Metabolism research while also leveraging data science and AI … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI, Alan Garber, Allston, Boston, cardiovascular, data science, drug discovery, Genentech, Harvard Enterprise Research Campus, Healthcare Innovation, Manu Chakravarthy, Maura Healey, METABOLISM, Michelle Wu, Mixed-Use Campus, partnership, Public Private Partnership, Renal, research and development, Roche, Roche Genentech Innovation Center Boston, Thomas Schinecker, USD11 Billion Investment
(IN BRIEF) QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestinal infections in the U.S. This new panel targets five major bacterial pathogens and complements the previously cleared QIAstat-Dx … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged bacterial pathogens, Campylobacter, clinical needs, diagnostic solutions, diagnostic workflows, FDA clearance, Gastrointestinal Infections, healthcare flexibility, healthcare providers, Infectious Diseases Society of America, laboratories, Nadia Aelbrecht, outpatient use, partnership, QIAGEN, QIAstat-Dx Gastrointestinal Panel 2 Mini B, QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, QIAstat-Dx Rise, QIAstat-Dx system, real-time PCR, Salmonella, Shigella, STEC, syndromic testing, Yersinia enterocolitica
(IN BRIEF) The European Investment Bank has committed €150 million to a pioneering financing initiative exclusively supporting women entrepreneurs in Spain’s pharmacy sector. The investment, delivered through a covered bond issued by CBNK—a bank formed by the merger of Banco … Read the full press release
Posted in Banks, Business, Economy, European Union, Financial, Government, Healthcare, Industrial, Investment, Luxembourg, Management, News, Pharma & Biotech, Science, Society, Spain, Technology
Tagged 000 loans, 600 pharmacies, Banco Caminos, Bancofar, CBNK, commercial bank advisory programme, EIB, EIB Group Forum, Enrique Serra González, equipment, European Commission, European Investment Bank, gender equality, Gender Finance Lab, inclusive economic growth, intermediated financing programme, InvestEU Advisory Hub, license acquisition, Luxembourg, Moody's Aa1 rating, Nadia Calviño, partnership, pharmacy sector, Spain, Spanish healthcare system, women entrepreneurs, working capital, €150 million investment, €450
(IN BRIEF) QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its European Patent EP 2 276 883 B2, which covers innovations in QuantiFERON-TB Gold Plus used for TB detection. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Law, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged bioMérieux, CDC, Düsseldorf, European Patent EP 2 276 883 B2, infectious disease diagnostics, intellectual property, latent tuberculosis, Molecular Diagnostics, patent lawsuit, public health, QIAGEN, QuantiFERON technology, QuantiFERON-TB Gold Plus, SD Biosensor, TB detection, Thierry Bernard, tuberculosis, tuberculosis control, Unified Patent Court, WHO
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
(IN BRIEF) The European Investment Bank (EIB) has signed a €20 million loan agreement with Universal DX, a Spanish startup pioneering blood-based liquid biopsy solutions for early cancer detection. The investment will accelerate the development and commercialization of their colorectal, … Read the full press release
(IN BRIEF) Quest Diagnostics has agreed to acquire select assets from Fresenius Medical Care’s Spectra Laboratories, expanding its portfolio with dialysis-related laboratory and water testing services. This collaboration will enhance the care and efficiency of dialysis services across the U.S., … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged chronic disease care, Chronic kidney disease, dialysis services, end-stage kidney disease, ESKD, Fresenius Medical Care, healthcare partnership, kidney disease diagnostics, laboratory services, Quest Diagnostics, U.S. healthcare, water testing
(IN BRIEF) Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupixent would be the first targeted medicine for BP in the U.S., with the FDA’s decision expected … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged bullous pemphigoid, chronic conditions, clinical trial, corticosteroid, disease remission, Dupixent, Dupixent sBLA, FDA approval, FDA priority review, orphan drug designation, regulatory news, Sanofi, skin disease, targeted treatment
(IN BRIEF) Recent studies suggest that current cardiovascular risk assessment methods may be inadequate and call for a more personalized approach. Tools like carotid ultrasound offer promising solutions for more precise evaluations, enabling targeted interventions such as aspirin therapy, which … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged aspirin therapy, Bayer, cardiovascular disease, cardiovascular health, Cardiovascular risk, carotid ultrasound, coronary artery calcium scoring, Dr. Michael Blaha, Dr. Ricardo Salazar, healthcare access, heart disease prevention, ischemic events, medical research, personalized medicine, risk assessment, stroke prevention, subclinical atherosclerosis, subclinical plaque
(IN BRIEF) Alexion, AstraZeneca Rare Disease, has partnered with DHL Express to become the first company in Ireland to fully transition its air freight operations to 100% Sustainable Aviation Fuel (SAF). This switch will reduce greenhouse gas emissions by over … Read the full press release
Posted in Aviation & Aerospace, Business, Energy, Gas & Oil, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, Transportation & Logistics, United Kingdom
Tagged 2050 net-zero goal, air freight, Alexion, AstraZeneca Rare Disease, AstraZeneca sustainability strategy, decarbonization, DHL Express, Emissions Reduction, environmental stewardship, Europe, European countries, global supply chain, GoGreen Plus service, greenhouse gas emissions, medicine transportation, net-zero emissions, partnership, SAF, Scope 3 emissions, Scope 3 GHG emissions, sustainability, sustainable aviation fuel
(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, acquisition, Anthos Therapeutics, anticoagulation, atrial fibrillation, biopharmaceutical company, Blackstone Life Sciences, bleeding reduction, Boston, cancer-associated thrombosis, cardiovascular, cardiovascular therapeutic area, clinical-stage, David Soergel, Factor XI inhibition, Fast Track Designation, FDA, medical research, Novartis, partnership, Phase 3 trials, regulatory milestones, Shreeram Aradhye, stroke prevention, systemic embolism, therapeutic focus, thrombosis
(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release
Posted in France, Healthcare, Marketing, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged Alfred Samuels, AstraZeneca, Azafaros, Beyza Klein, Biotech, Biotechnology Conference, Boehringer Ingelheim, Bre Bugbee-Barrett, Catherine Coulouvrat MD, Chiesi Farmaceutici SpA, clinical development, clinical operations, clinical research, clinical research enterprise, clinical trial, clinical trials, Conference Forum, decentralized clinical trials, Gisela Linthorst, GSK, Harry Verbunt, HTA/Regulatory requirements, Johnson & Johnson Innovative Medicine, Lea-Isabelle Proulx PhD, life post-cancer diagnosis, Marisa Minetti, Medicine Development, Patient Advocacy, patient engagement, patient engagement in drug development, patient experience, Patient Recruitment, Patient Retention, Patients as Partners, Patients as Partners Europe, Peter DiBiaso, pharma, Pharmaceutical Conference, Regeneron, research and development, Roche, Royal National Hotel, Sanofi, Temi Olonisakin MD, The Conference Forum, Valerie Bowling
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
(IN BRIEF) SCHOTT Pharma’s AGM on February 4, 2025, revealed strong fiscal results for FY 2024, including exceeding revenue targets and a promotion to the MDAX. Shareholders approved all agenda items, including the appointment of Dr. Wolfram Carius to the … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annual General Meeting, appointment, corporate growth, dividend payout, Dr. Wolfram Carius, GLP-1 drugs, green financing, homecare solutions, INNOVATION, KPMG, leadership, Management, MDAX, mRNA, pharma industry, profitability, revenue guidance, SCHOTT Pharma, shareholder approval, shareholder engagement, Supervisory Board
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a monotherapy to treat limited-stage small cell lung cancer (LS-SCLC) in patients whose disease … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADRIATIC Phase III trial, AstraZeneca, CHMP, disease progression, durvalumab, EMA, European Medicines Agency, hazard ratio, Imfinzi, immunotherapy, limited-stage small cell lung cancer, LS-SCLC, monotherapy, overall survival, platinum-based chemoradiation therapy, progression-free survival, regulatory review, safety profile, Small cell lung cancer, Suresh Senan, survival outcomes, Susan Galbraith, The New England Journal of Medicine, treatment approval
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, biosimilars, Business Growth, Chief Executive Officer, commercial strategy, Country President, Francisco Ballester, generics, Global Platform Head, Health Management and Policy Advisory Council, leadership, M&A, Miami Herbert Business School, patient access, Peter Stenico, Pro Generika, Region International, retirement, Richard Saynor, Sandoz, Sandoz Austria, Sandoz Executive Committee
(IN BRIEF) Krka achieved a score of 56 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment, ranking the company among the top 10% of pharmaceutical firms. This marks an improvement over the previous year’s performance and highlights … Read the full press release
Posted in Awards, Business, Environment, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged Awards, business ethics, environmental protection, ESG, good manufacturing practice, Governance, health and well-being, integrity, Krka, leadership, patient care, pharmaceutical industry, quality medicines, S&P Global Corporate Sustainability Assessment, social responsibility, sustainability, transparent operations
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?